A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer

NCT02982954 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

211

Enrollment

INDUSTRY

Sponsor class

Conditions

Renal Cell Carcinoma

Interventions

DRUG: Nivolumab
DRUG: Ipilimumab

Sponsor

Bristol-Myers Squibb